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Abstract  
INTRODUCTION: Diabetes’ relationship to specific neuropathological causes of dementia is incompletely 
understood. 
METHODS: We used logistic regression to evaluate the association between diabetes and infarcts, Braak 
stage, neuritic plaque score, and level of Alzheimer’s neuropathological changes in 2,365 autopsied 
persons. In a subset of >1,300 persons with available cognitive data, we examined the association 
between diabetes and cognition using Poisson regression. 
RESULTS: Diabetes increased odds of brain infarcts (OR=1.57, P<0.0001), specifically lacunes (OR=1.71, 
P<0.0001), but not Alzheimer neuropathology. Diabetes plus infarcts was associated with lower 
cognitive scores at end of life than infarcts or diabetes alone, and diabetes plus high level of Alzheimer’s 
neuropathological changes was associated with lower MMSE scores than the pathology alone. 
DISCUSSION: This study supports the conclusions that diabetes increases the risk of cerebrovascular but 
not Alzheimer’s pathology, and at least some of diabetes’ relationship to cognitive impairment may be 
modified by neuropathology. 
 
 
Keywords: diabetes, neuropathology, infarcts, autopsy, cognition, cerebrovascular, Alzheimer 
 
Abbreviations: SMART: Statistical Modeling of Aging and Risk of Transition study; BRAiNS: Biologically 
Resilient Adults in Neurological Studies; ROS: Religious Orders Study; HAAS: Honolulu-Asia Aging Study; 
mABC: modified Alzheimer’s disease neuropathologic change rating based on Aβ plaque score, Braak 
NFT (neurofibrillary tangle) stage, and CERAD NP (neuritic plaque) score.  
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1. Introduction 
A strong body of evidence links diabetes to cognitive dysfunction and dementia, including 
clinically diagnosed Alzheimer’s disease (AD) and vascular dementia. Insulin resistance [1-3] and glucose 
levels [4] have both been suggested as driving factors in the diabetes-dementia relationship. Many 
researchers argue that diabetes and AD are closely linked, with shared biochemical etiologies [5], and 
these hypotheses are supported by epidemiological studies that identified increased incidence of clinical 
AD for people with diabetes [6-9]. Positron emission tomography (PET) imaging shows evidence of 
glucose metabolic changes early in life among individuals at risk for developing AD [10]. Neuroimaging 
studies have reported conflicting results regarding insulin resistance: Willette and colleagues (2015) [10] 
reported increased amyloid deposition in normoglycemic, late middle-aged adults with higher levels of 
insulin resistance [11], while Thambisetty and colleagues (2013) reported no association [12]; both 
studies used 11C-Pittsburgh compound B PET, although insulin resistance was measured differently. 
Insulin resistance has also been reported to be associated with higher cerebrospinal fluid tau levels in 
APOE-ε4 allele carriers [13] and is increased in brain tissue in early AD [14].  
Despite data linking diabetes and clinical AD, there are strong arguments that diabetes may not 
exacerbate AD neuropathology.  Clinicopathological studies have largely been unable to demonstrate 
higher burden of AD neuropathology in persons with diabetes [15-18], except perhaps in APOE-ε4 allele 
carriers [7, 9]. By contrast, studies often report increased cerebrovascular pathology [7, 9, 17]. 
Epidemiological, clinical, and neuroimaging studies have also identified increased risk of cerebrovascular 
disease (CVD) linked to diabetes [19-21]. 
We re-examined the association between diabetes and neuropathology in a large 
clinicopathological study (>2,000 total autopsies) drawn from the Statistical Modeling of Aging and Risk 
of Transition (SMART) database, a consortium of longitudinal studies of aging and cognition [22]. We 
assessed AD neuropathology and cerebral infarctions in aged participants with and without diabetes, 
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controlling for age at death, sex, research center, and other potential confounders in a series of 
regression models. We also evaluated the relative impact of diabetes on cognition using Mini-Mental 
State Exam (MMSE) and Animal Naming Test (Animals) scores obtained near death. 
2. Methods 
2.1 Sample 
Cases were drawn from participants in the SMART database [22]. Briefly, the database 
comprises a standardized set of data elements contributed by 11 longitudinal studies of aging and 
cognition. Most included cohorts have lengthy follow-up and high autopsy rates. Cohorts that required 
or encouraged brain donation and collected information on diabetes are included in the current study. 
Since not all deceased participants came to autopsy, and not all autopsies were included in the current 
study, we assessed selection bias by comparing the included participants to all deceased participants in 
the included cohorts with respect to age at death, gender, APOE-ε4, cohort, and diabetes.  Inclusion 
criteria for the current study were known diabetes status and non-missing data on at least one 
neuropathological measure of both Alzheimer’s disease (either Braak neurofibrillary tangle [NFT] stage 
[23] or Consortium to Establish a Registry in Alzheimer’s Disease [CERAD] neuritic plaque [NP] rating 
[24]), and infarct neuropathology (large artery infarcts, lacunes, or microinfarcts). Based on availability 
of necessary variables, participants from the following cohorts were included: Honolulu-Asia Aging Study 
(HAAS) [25], Oregon Brain Aging Study [26], African American Dementia Project (see [22]), Klamath 
Exceptional Aging Project [27], Religious Orders Study (ROS) [28], Rush Memory and Aging Project (Rush 
MAP) [29], Memory and Aging Project at Washington University [30], and Biologically Resilient Adults in 
Neurological Studies (BRAiNS) [31]. Research procedures were approved by Institutional Review Boards 
at each cohort’s home institution. All participants provided written informed consent. 
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2.2 Determination of diabetes 
We determined diabetes status by self-report or by reported use of antidiabetic medication, as 
previously described in ROS [32], Rush MAP [33], HAAS [7], and BRAiNS [34]. Although Type 1 and Type 2 
diabetes were not differentiated, given the rarity of Type 1 diabetes in participants over age 60 and 
especially over age 80 [35], we assumed that diabetes reports comprised Type 2 diabetes (hereafter 
“diabetes”). Laboratory blood measures were not available in the SMART database, and therefore were 
not examined in the present study.  
2.3 Neuropathological outcomes 
Autopsies were conducted within the original cohort studies [25, 26, 30, 31, 36, 37]. The 
association between diabetes and neuropathology has been examined previously in some included 
cohorts—HAAS [7], ROS [32], and BRAiNS [34]—but new endpoints are assessed and many additional 
participants are included in the current study. Neuropathological assessments were performed blind to 
clinical data. Neuropathological data were scored according to a format of the National Alzheimer’s 
Coordinating Center (NACC) dataset, as described previously [22], because most SMART 
neuropathologists contribute to NACC (see 
https://www.alz.washington.edu/NONMEMBER/NP/rdd_np.pdf).  Briefly, study neuropathologists made 
determinations of Braak NFT stage [23]; CERAD NP rating (None, Sparse, Moderate, or Frequent) [24]; 
diffuse plaque rating (None, Sparse, Moderate, or Frequent); and presence of large artery cerebral 
infarcts, lacunes, and cortical microinfarcts. “Large” infarcts were defined as any infarct with maximum 
diameter greater than 1 cm; lacunes were defined as infarcts or hemorrhages 1 cm or less in diameter in 
the small parenchymal vessels, but visible to the naked eye; and microinfarcts were defined as cortical 
infarcts detected microscopically only.  
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Since Thal phases (A immunohistochemistry) were unavailable, we constructed a modified 
version of the National Institute on Aging-Alzheimer’s Association criteria for AD neuropathological 
change (the “ABC” score) [38], that addressed the cases where diffuse amyloid plaque neuropathology 
may be present without neuritic amyloid plaques. Thus, we collapsed the concept of diffuse amyloid 
deposits to a dichotomous “Ad” variable.  We considered the presence of any diffuse plaques to be Ad=1, 
while absence of any diffuse plaques was 0. High level of AD changes corresponded to an Ad score of 1 
plus Braak NFT stage V/VI plus CERAD NP rating of Frequent or Moderate. Intermediate level of AD 
changes corresponded to an Ad score of 1 plus either Braak NFT stage V/VI plus None or Sparse CERAD 
NP or Braak III/IV plus Frequent or Moderate CERAD NP. Low level of AD changes corresponded to an Ad 
score of 1 plus either Braak NFT stage III/IV plus None or Sparse CERAD NP or Braak NFT stage 0/I/II. No 
AD changes corresponded to an Ad score of 0 (absence of diffuse plaques) to enable compatibility with 
the new consensus-based diagnostic criteria. 
2.4 Covariates 
Participant age at death (centered at 85 years), sex (female=1, male=0), education (years), 
APOE-ε4 carrier status (any ε4 alleles=1, no ε4 alleles=0), hypertension (yes=1, no=0), and research 
center were included as potential confounders.  
2.5 Cognitive data 
Global cognition was estimated using the MMSE [39] and category fluency using Animals [40] in 
participants for whom those scores were available. Two sets of scores were examined: scores obtained 
within two years of death, and scores obtained six years prior to death.  MMSE and Animals were 
selected because all cohorts administered Animals, and all cohorts except for one administered the 
MMSE.  
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2.6 Statistical Analysis 
All statistical analyses were performed using SAS 9.4® (SAS Institute, Inc; Cary, NC). Two-group 
comparisons of potential confounding variables for participants with and without diabetes were made 
using t tests for interval-level variables and chi-square tests for categorical variables. We used case-
control designs, where cases demonstrated the neuropathological outcome of interest and controls 
were free of the neuropathology, to estimate adjusted odds ratios (OR) and 95% confidence intervals 
(CI) for the association between neuropathological outcomes and diabetes. For multi-level variables 
(mABC rating, Braak NFT stage, and CERAD NP score), we used the “absent” category (e.g., CERAD NP 
score of ‘None’) as the reference level and computed an OR for each stratum separately; we conducted 
sensitivity analyses using ordinal logistic regression models. 
To address confounding, we used logistic regression to estimate adjusted ORs. For each 
dependent neuropathological measure, we constructed two models. The first model included control 
variables age at death, sex, and center. The second model included these variables plus education, 
hypertension, and APOE-ε4 status. There was a loss in sample size in the second model due to missing 
data in some of the additional variables. Significance for neuropathological models was set at 0.05, but 
we also used the Holm-Bonferroni procedure to assess the robustness of the results given there were 26 
comparisons made.  
Last, we evaluated the association between diabetes and end-of-life global cognition and 
category fluency. We estimated mean scores using Poisson regression and controlled for 
neuropathology (mABC rating, and, in separate models, any infarcts or lacunes). Interactions between 
diabetes and neuropathology were tested in the initial models. We adjusted mean scores for age at 
death, education, sex, center, and time (in years) since last assessment. Given the lengthy follow-up of 
most SMART cohorts, we also examined adjusted mean MMSE and Animals scores for participants with 
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scores available six years prior to death. Assessments that occurred between 5.5 and 6.5 years prior to 
death were included in this analysis. Significance for cognitive models was set at 0.05.  
3. Results 
There were 6,143 deaths in the included cohorts. Of the 2,429 total autopsies, 2,365 (97.4%) 
were included in the current study. Participant inclusion is shown in Figure 1. Probability of inclusion in 
the present study, conditioned on death, was independent of diabetes and depended only on cohort 
(P<0.0001), since cohorts had different protocols for obtaining brain donation, and on age, such that a 1-
year increase in age at death increased the odds of inclusion by about 1% (P=0.048). Sex, APOE, and 
diabetes status had no association with the probability of inclusion in the study after controlling for 
cohort. 
Participants with diabetes (n=507; 21.4% of total sample) died younger, had lower educational 
attainment, and were more likely to have hypertension than participants without diabetes (n=1,858) 
(Table 1). Last cognitive diagnosis was similar by diabetes status, and where dementia subtype was 
classified, proportions of clinical AD (68% vs. 73%) and vascular dementia (29% vs 22%) were similar in 
participants with and without diabetes, respectively (P=0.33). APOE-ε4 carrier status was similar among 
those with and without diabetes. APOE was missing in 1.8% of cases with and in 2.2% of cases without 
diabetes. Because participants without diabetes were almost twice as likely to be missing hypertension 
(7.9% vs. 4.3%), we performed a sensitivity analysis that assumed all missing cases in the no diabetes 
group had hypertension; the proportion with hypertension in the diabetes group remained significantly 
higher than in those without diabetes (χ2=36.2, P<0.0001). Diabetes was reported during follow-up for 
an average of 6.8±4.6 years.  
Neuropathological outcome measures were incompletely observed in only a small proportion of 
cases, with the exception of microinfarcts, which were missing in 23% of participants with diabetes 
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(Table 2). Participants with diabetes had an estimated 54-57% increased odds of having any infarct 
(P<0.0001 in Model 1; P=0.001 in Model 2) and had an estimated 71-77% increased odds of having 
lacunes (P<0.0001 in both models) (Table 3). Prevalence of large infarcts and microinfarcts did not differ 
by diabetes status, but participants with diabetes had marginally increased odds of having three infarct 
types observed (P=0.05, Model 1; P=0.04, Model 2). There was no statistically significant association 
with AD neuropathology, although there was some evidence that Low or Intermediate level of AD 
neuropathology (vs. None) may be more common among participants with diabetes (Table 3). Results 
were similar when we used ordinal rather than stratified logistic models (data not shown). 
The association of diabetes with cognitive scores was modified by presence of any infarcts 
(P=0.0016 for interaction; see Table 4 for means). Specifically, diabetes was associated with end-of-life 
global cognition (MMSE) and category fluency (Animals) for participants with any infarcts. The presence 
of diabetes in the absence of any infarcts was not associated with worse scores on either measure, but 
participants who had both diabetes and any infarcts were significantly worse on both measures than 
participants with infarcts alone (MMSE: ∆=-1.1 points, P=0.0002;  Animals: ∆=-0.6 points, P<0.0001). 
Results were similar for lacunes (Table 4). For participants with ‘High’ mABC rating, diabetes was 
associated with lower MMSE scores than participants with ‘High’ mABC but without diabetes (14.3 vs. 
16.1; P=0.0008); MMSE scores did not vary by other levels of mABC according to diabetes status. There 
was no difference in Animals scores associated with diabetes and mABC (P=0.27). When neuropathology 
was removed from the models, diabetes had no significant effect on either mean MMSE or Animals 
scores. For assessments made six years prior to the end of life diabetes had no effect on mean MMSE or 
Animals scores, either by modifying the effect of neuropathology, which was specified identically to the 
previous models, or as a main effect (data not shown). As with end-of-life scores, diabetes had no 
significant association with mean MMSE or Animals scores obtained six years prior to death when 
neuropathology was removed from the models. In a sensitivity analysis examining slopes of change 
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between two and six years before death, we found no mean differences associated with diabetes (data 
not shown). 
4. Discussion 
Results from this autopsy study of about 2,400 older persons with and without diabetes, the 
largest to date, confirm that diabetes is significantly associated with brain infarction, specifically lacunes. 
We also found that diabetes in combination with infarcts was associated with lower MMSE and Animals 
scores at the end of life compared to infarcts alone. By contrast, in this large sample, there was little 
evidence that diabetes was associated with any AD neuropathology measure (global or more specific 
measures). For participants with the highest level of AD changes, diabetes was associated with lower 
mean MMSE but not Animals scores. 
The link between diabetes and CVD has been demonstrated repeatedly in the scientific, 
including epidemiologic, literature [19, 41-43]. The mechanisms through which diabetes causes CVD 
remain incompletely understood, but may involve insulin resistance, high fasting blood glucose, 
hypertension, comorbid abdominal obesity, carotid disease, endothelial dysfunction, and 
hypercoagulation, among other mechanisms (see [44] for a review). 
Neuropathological studies have repeatedly identified increased CVD, specifically brain 
infarction, in association with diabetes, [9, 17, 32, 34]. However, the results are somewhat more 
heterogeneous than this statement suggests. Sonnen and colleagues reported increased microvascular 
infarcts in persons with diabetes, but only when dementia was also present [17]. Similarly, Nelson and 
colleagues reported increased microinfarcts but without regard to cognitive status [34]. They also 
reported an increase in the presence of any infarct (including large infarcts, lacunes, microinfarcts, and 
hemorrhagic infarcts). By contrast, Arvanitakis and colleagues [32] and Ahtiluoto and colleagues [9] 
identified macroscopic infarcts, visible to the naked eye, regardless of size, and found a positive 
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association. In the current study, we found that diabetes was associated with any infarct (any large 
infarct, lacune, and/or microinfarct) and also lacunes specifically. An association between diabetes and 
lacunes has also been reported in neuroimaging studies [45]. Although we did not find a relationship 
between microinfarcts and diabetes such as has been previously reported [17, 34], the substantial 
proportion of missing data on microinfarcts in participants with diabetes compared to those without 
(23% vs 12%, P<0.0001) may affect comparability.  
As with CVD, epidemiologic studies have largely identified increased risk of AD for people with 
diabetes [6-9], although some have not [42, 46]. In experimental studies, including in postmortem 
human tissue, brain insulin resistance has been identified as a feature of early AD [14], and abnormal 
serine phosphorylation of insulin receptor substrate 1 was shown to be elevated in AD brains [3, 47] and 
to be associated with pathologic tau in neurons [47]. Animal studies have reported that anti-diabetes 
agents may protect against Aβ-induced defective insulin signaling [3] and reverse increases in Aβ levels 
induced through high-fat diet [48]. 
Two autopsy-based studies of diabetes or related measures reported increased AD 
neuropathology. Peila et al. [7] examined 216 cases from HAAS (a subset of the 769 cases from HAAS 
included in the present study) and reported increased NFT in the hippocampus and cortex and increased 
NP in the hippocampus for participants with both diabetes and APOE-ε4 allele, compared to participants 
without either factor. This group did not have increased AD neuropathology compared to participants 
with APOE-ε4 alone. Participants with diabetes alone did not have increased AD neuropathology on any 
measure compared to participants without either factor. Matsuzaki et al. [1] reported on 135 autopsies 
from participants in a population-based study of residents in Hisayama, Japan. Blood-based measures of 
diabetes obtained 10-15 years prior to death were used to predict Braak stage and CERAD NP score. No 
associations with Braak stage were detected, but increases in 2-hour post-challenge glucose, fasting 
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insulin, and insulin resistance were associated with increased odds of any NP (but no graded effect for 
increased NPs). APOE-ε4 plus hyperglycemia also increased odds of any NP. 
Most studies with autopsy-verified measures have not supported a positive association between 
diabetes and amyloid or tau neuropathology. The absence of an autopsy-verified diabetes-AD 
relationship in these studies is conspicuous, considering that AD markers were measured and quantified 
with a variety of techniques, including immunocytochemistry [15], immunohistochemistry [7, 9, 16, 32, 
34], silver staining [9, 32, 34], and biochemical analysis [17]. Moreover, the lack of positive association 
between diabetes and frequency or severity of AD neuropathology is independent of the 
operationalization of neuropathology: Braak NFT staging [15, 17, 34], NFT density [9, 18, 32, 34], CERAD 
NFT [16] and NP ratings [15, 16, 17, 34], NP density [9, 18, 34], β-amyloid protein burden [9, 32], and, 
here, modified ABC rating.  
In addition to the association of diabetes with brain infarction, we also found that diabetes, in 
combination with any brain infarction, as well as lacunes specifically, was associated with significantly 
lower MMSE and Animals scores at the end of life. It is unclear why diabetes was associated with 
cognitive impairment only near death, and future research should address more directly the temporal 
relationship between diabetes and cognitive outcomes. We did not find a strong relationship to 
cognition for diabetes alone or in combination with mABC score, although participants with ‘High’ mABC 
and diabetes had significantly lower MMSE scores, but not Animals scores, than participants with ‘High’ 
mABC but without diabetes. However, results pertaining to cognitive scores should be interpreted with 
caution. Participants with diabetes were more likely to be missing MMSE scores (26.6% vs. 18.0% 
missing, P<0.0001), and participants with missing Animals scores tended to be older. For both 
instruments, participants with missing data were less educated, were more likely to have any infarcts 
and were less likely to have high or intermediate mABC rating (data not shown). 
13 
 
Our study has several strengths. This is the largest study to date of diabetes and neuropathology 
of AD and CVD.  We used data from detailed neuropathological assessments. This is the first study, to 
our knowledge, to examine the association between diabetes and ABC rating. We also used other 
established methods to diagnose or stage AD neuropathology. There was no evidence of selection bias 
with regard to sex, education, APOE, or diabetes status within each cohort. 
This study has some limitations. This is an observational study, and causal relationships cannot 
be established. Although we controlled for confounding factors, we did not have available data on 
adiposity or smoking habits; smoking is likely related to both risk of cerebrovascular pathology and other 
lifestyle factors that may be related to diabetes. Diabetes was ascertained via self-report and medication 
inspection rather than laboratory blood measures, so cases were likely missed. We used semi-
quantitative rather than quantitative measures of neuropathology, but as noted above findings in this 
area have been rather consistent independent of the neuropathological methods used. We used a 
modified ABC rating due to unavailability of Thal phases; this may have resulted in a very small 
proportion of cases receiving a different ABC classification than they would have otherwise. This study 
combined autopsied cases assessed by multiple neuropathologists, who may have had slightly different 
criteria for classifying neuropathology. However, we also view this as a strength because a multi-center 
approach, which synthesizes findings from multiple pathologists, approximates the experience of 
community neuropathologists. Finally, our findings may not be generalizable to the general older adult 
population given the differences in recruitment methods and source populations in each cohort. 
Nonetheless, overall the findings are consistent with previous literature. 
Based on our results, and the results of many prior clinicopathological studies, diabetes, 
measured as a dichotomous variable, is unlikely to be significantly associated with AD neuropathology 
but is likely to be significantly associated with CVD pathology. However, diabetes is heterogeneous. 
Individuals differ in disease severity and duration, treatments used, comorbidities, and lifestyle factors. 
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More research is needed to better account for these complicating factors, as well as survival bias or 
perhaps compensatory mechanisms that may be at play, and identify subgroups that may be at 
increased risk for AD. 
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Tables 
Table 1. Demographic and clinical characteristics of autopsied SMART subjects with known diabetes 
status and available neuropathological data 
 All subjects 
(N=2,365) 
Diabetes 
(N=507) 
No Diabetes 
(N=1,858) P value* 
Age at death, years 88.7±6.5 87.8±6.0 89.0±6.6 <0.0001 
Female (n [%]) 1009 (42.7) 147 (29.0) 862 (46.4) <0.0001 
Education, years 14.1±4.2 13.7±4.2 14.3±4.2 0.002 
Hypertension (n [%]) 1,600 (67.7) 413 (81.5) 1,187 (63.9) <0.0001 
APOE-ε4 carrier (n [%]) 543 (23.0) 103 (20.3) 440 (23.7) 0.12 
Last clinical diagnosis (n [%])    0.69 
   Intact cognition 948 (40.1) 204 (40.2) 744 (40.0)  
   Mild Cognitive Impairment 473 (20.0) 95 (18.7) 378 (20.3)  
   Dementia 908 (38.4) 198 (39.1) 710 (38.2)  
   Other/Unknown 36 (1.5) 10 (2.0) 26 (1.4)  
MMSE, 6 years prior to death† 27.0±3.8 27.3±3.0 26.9±4.0 0.20 
MMSE, ≤ 2 years of death‡ 22.2±8.4 21.9±8.4 22.2±8.4 0.58 
Animals, 6 years prior to death§ 15.0±5.6 14.8±5.7 15.1±5.6 0.63 
Animals, ≤ 2 years of death¶ 10.7±6.1 10.1±5.9 10.9±6.1 0.032 
*Comparisons are Diabetes vs. No Diabetes; diabetes is determined by self-report or report of antidiabetes 
medication use. †Diabetes, n=179; No Diabetes, n=746. ‡Diabetes, n=244; No Diabetes, n=1092.  §Diabetes, 
n=200; No Diabetes, n=775. ¶Diabetes, n=339; No Diabetes, n=1167. Results presented are mean ± standard 
deviation unless otherwise noted. 
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Table 2. Cerebrovascular disease and Alzheimer’s disease neuropathologies (N=2,365).  
Neuropathology (n [%]) 
Diabetes 
(N=507) 
No Diabetes 
(N=1,858) P value* 
Cerebrovascular disease pathology    
     Any infarcts 354 (69.8) 1,105 (59.5) <0.0001 
        Missing any infarcts† 24 (4.7) 62 (3.3)  
     Large artery infarcts‡ 129 (25.4) 389 (20.9) 0.034 
        Missing large artery infarcts  2 (0.4) 16 (0.9)  
     Lacunes§ 283 (55.8) 749 (40.3) <0.0001 
        Missing lacunes  4 (0.8) 24 (1.3)  
     Microinfarcts¶ 140 (27.6) 519 (27.9) 0.11 
        Missing microinfarcts 118 (23.3) 226 (12.2)  
     Number of infarct types    <0.0001 
         0 153 (30.2) 753 (40.5)  
         1 202 (39.8) 661 (35.6)  
         2 106 (20.9) 336 (18.1)  
         3 46 (9.1) 108 (5.8)  
Alzheimer’s disease neuropathology     
    Braak NFT stage    
       0/I/II 160 (31.6) 512 (27.6) ref 
       III/VI 213 (42.0) 793 (42.7) 0.20 
       V/VI 102 (20.1) 418 (22.5) 0.08 
       Missing  32 (6.3) 135 (7.3)  
    CERAD neuritic plaque rating    
        None 161 (31.8) 566 (30.5) ref 
        Sparse 110 (21.7) 374 (20.1) 0.86 
        Moderate 154 (30.4) 566 (30.5) 0.42 
        Frequent 82 (16.2) 384 (20.7) 0.022 
        Missing 0 0  
     Modified Alzheimer’s ABC rating#    
        No AD changes 138 (27.2) 472 (25.4) ref 
        Low AD changes 149 (29.4) 481 (24.9) 0.67 
        Intermediate AD changes 119 (23.5) 462 (24.9) 0.37 
        High AD changes 86 (17.0) 357 (19.2) 0.21 
        Missing 15 (3.0) 86 (4.6)  
*P values are for results of chi-square tests. †Participant has no recorded infarcts but is missing data for at least 
one infarct type.  ‡One or more large artery cerebral infarcts. §One or more lacunes (small artery infarcts and/or 
hemorrhages).  ¶One or more cortical microinfarcts (including granular atrophy). #High AD changes = presence any 
diffuse plaques plus Braak V/VI plus Frequent or Moderate neuritic plaques; Intermediate AD changes = presence 
of any diffuse plaques plus EITHER Braak V/VI plus None or Sparse neuritic plaques OR Braak III/IV plus Frequent or 
Moderate neuritic plaques; Low AD changes = presence of any diffuse plaques plus EITHER Braak III/IV plus None 
or Sparse neuritic plaques OR Braak 0/I/II; No AD changes = absence of diffuse plaques.  
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Table 3. Adjusted odds ratios for diabetes given presence of cerebrovascular disease and Alzheimer’s 
disease neuropathology.  
Neuropathology 
(Dependent variable) 
Model 1* 
OR (95% CI) 
Model 2†  
OR (95% CI) 
Cerebrovascular pathology  
(present vs. absent) 
  
  Any infarcts  1.57 (1.23, 2.00) ‡§ 1.54 (1.19, 2.00) ‡§ 
  Large artery infarcts  1.19 (0.94, 1.51) 1.17 (0.92, 1.49) 
  Lacunes  1.71 (1.39, 2.12) ‡§ 1.77 (1.42, 2.20) ‡§ 
  Microinfarcts  1.17 (0.90, 1.53) 1.16 (0.88, 1.54) 
  Three infarct types reported 1.44 (1.00, 2.09) 1.48 (1.01, 2.16)‡ 
Alzheimer’s disease pathology   
  Braak NFT stage   
      V/VI vs. 0/I/II 0.82 (0.61, 1.11) 0.97 (0.70, 1.35) 
      III/IV vs. 0/I/II 0.92 (0.72, 1.18) 0.99 (0.76, 1.29) 
  CERAD neuritic plaque rating   
     Frequent vs. None 0.96 (0.68, 1.36) 1.25 (0.83, 1.87) 
     Moderate vs. None 1.02 (0.78, 1.33) 1.11 (0.83, 1.48) 
     Sparse vs. None 0.98 (0.73, 1.30) 1.07 (0.79, 1.46) 
  Modified Alzheimer’s ABC rating   
      High vs. No AD changes 1.05 (0.76, 1.46) 1.13 (0.77, 1.65) 
      Intermediate vs. No AD changes 1.17 (0.86, 1.60) 1.34 (0.96, 1.87) 
      Low vs. No AD changes 1.22 (0.92, 1.60) 1.31 (0.98, 1.76) 
*Odds ratios are adjusted for age at death (centered at 85), female sex (1, 0), and research center (Honolulu-Asia 
Aging Study, Oregon Health & Science University, Rush University Medical Center, Washington University, or 
University of Kentucky). †In model 2, years of education, history of hypertension (1, 0), and APOE-ε4 carrier status 
(1, 0) are included as additional control variables. ‡P value significant at 0.05. §P value statistically significant after 
applying Holm-Bonferroni procedure.  
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Table 4. Adjusted end-of-life mean Mini-Mental State Examination (MMSE) and Animal Naming 
(Animals) scores* 
Participant group 
MMSE 
(n=1,317) 
Animals 
(n=1,335) 
(1) Diabetes + any infarcts           20.8 (0.4)†, ‡, § 9.4 (0.3)†, ‡, § 
(2) No Diabetes + any infarcts     21.9 (0.3)¶ 10.0 (0.2)¶ 
(3) Diabetes + no infarcts             24.9 (0.5) 11.5 (0.4) 
(4) No Diabetes + no infarcts       23.7 (0.3) 11.3 (0.2) 
Participant group 
MMSE 
(n=1,302) 
Animals 
(n=1,128) 
(1) Diabetes + lacunes 20.8 (0.5)†, ‡, § 10.1 (0.4)†, ‡, § 
(2) No diabetes + lacunes 22.2 (0.3)** 11.0 (0.3)¶ 
(3) Diabetes + no lacunes 24.3 (0.5) 12.5 (0.4) 
(4) No diabetes + no lacunes 23.2 (0.3) 12.2 (0.2) 
*Scores obtained within two years of death. Results are mean (SEM). Means are adjusted for modified 
ABC rating, age at death, education, female sex, research center, and time between last assessment and 
death. †(1) vs. (2) P<0.05 ‡(1) vs. (3) P <0.0001. §(1) vs. (4) P <0.0001.  ¶(2) vs. (4) P <0.0001. #(1) vs. (2) 
P < 0.05 **(2) vs. (4) P < 0.05.  
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Figures 
Figure 1. Participant inclusion flow diagram 
 
a. Honolulu-Asia Aging Study (n=769), the Oregon Brain Aging Study I and II (n=77 and 32), the African 
American Dementia Project (n=1), the Klamath Exceptional Aging Project (n=80), the Religious Orders 
Study (n=555), the Memory and Aging Project at Rush University Medical Center (n=454), the Memory 
and Aging Project at Washington University (n=126), and the Biologically Resilient Adults in Neurological 
Studies (n=271).  
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(2.1% of autopsies) 
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(97.4% of autopsies) 
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